Ryvu Therapeutics Past Earnings Performance

Past criteria checks 0/6

Ryvu Therapeutics's earnings have been declining at an average annual rate of -18.4%, while the Life Sciences industry saw earnings growing at 13.7% annually. Revenues have been growing at an average rate of 23.7% per year.

Key information

-18.4%

Earnings growth rate

-10.9%

EPS growth rate

Life Sciences Industry Growth26.0%
Revenue growth rate23.7%
Return on equity-58.6%
Net Margin-114.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

The Market Lifts Ryvu Therapeutics S.A. (WSE:RVU) Shares 26% But It Can Do More

Dec 07
The Market Lifts Ryvu Therapeutics S.A. (WSE:RVU) Shares 26% But It Can Do More

Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt

Oct 20
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt

We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate

Aug 02
We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate

Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?

Jan 25
Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?

What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?

Feb 05
What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?

Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return

Dec 14
Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return

Revenue & Expenses Breakdown

How Ryvu Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

WSE:RVU Revenue, expenses and earnings (PLN Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2491-1041560
30 Jun 2482-961460
31 Mar 2474-941370
31 Dec 2367-921230
30 Sep 2384-731150
30 Jun 2388-661100
31 Mar 2380-75910
31 Dec 2268-84850
30 Sep 2250-94790
30 Jun 2237-105720
31 Mar 2236-92680
31 Dec 2135-79640
30 Sep 2126-72590
30 Jun 2125-61560
31 Mar 2130-41510
31 Dec 2037-32510
30 Sep 2038-40530
30 Jun 2041-32540
31 Mar 2017-41450
31 Dec 1934-44560
30 Sep 1953-53430
30 Jun 1919-60190
31 Mar 19116-28930
31 Dec 1852-23260
30 Sep 18492400
30 Jun 189614650
31 Mar 1810221610
31 Dec 171056580
30 Sep 1710413550
30 Jun 179714530
31 Mar 178010480
31 Dec 16663470
30 Sep 16600490
30 Jun 1660-1450
31 Mar 16573400
31 Dec 15566350
30 Sep 15517280
30 Jun 15487260
31 Mar 15467260
31 Dec 14416240
30 Sep 14434220
30 Jun 14352200
31 Mar 1427-1170

Quality Earnings: RVU is currently unprofitable.

Growing Profit Margin: RVU is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RVU is unprofitable, and losses have increased over the past 5 years at a rate of 18.4% per year.

Accelerating Growth: Unable to compare RVU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RVU is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.4%).


Return on Equity

High ROE: RVU has a negative Return on Equity (-58.59%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 02:00
End of Day Share Price 2025/01/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ryvu Therapeutics S.A. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamil KliszczBiuro maklerskie mBanku
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Jonas PeciulisEdison Investment Research